Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
P/B ratio for Milestone Pharmaceuticals Inc. (MIST)
P/B ratio as of 2023: 4.28
According to Milestone Pharmaceuticals Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.28. At the end of 2022 the company had a P/B ratio of 2.53.
P/B ratio history for Milestone Pharmaceuticals Inc. from 2017 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 4.28 |
| 2022 | 2.53 |
| 2021 | 2.43 |
| 2020 | 1.37 |
| 2019 | 2.20 |
| 2018 | -6.58 |
| 2017 | -10.97 |